Ophthalmology Phase 3 Readout Calendar
Industry-sponsored ophthalmology trials with primary completion in the next 12 months or last 12 months.
Data last updated September 20, 2026 · source: ClinicalTrials.gov
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 ophthalmology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Ophthalmology landscape →
Recently read out & awaiting topline — Ophthalmology
· 3Phase 3 ophthalmology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Alcon Research | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction | Ocular Hypertension +1 | Completed | Q2 2026 2026-04-06 | Completed · awaiting
Updated 5mo ago
| NCT07082816 |
| AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma | Open-Angle Glaucoma | Completed | Q1 2026 2026-02-04 | Completed · awaiting
Updated 7mo ago
| NCT05411198 |
| Apellis Pharmaceuticals, Inc. | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe Asset: APL-2, Pegcetacoplan | Geographic Atrophy Secondary to Age-related Macular Degeneration | Completed | Q4 2025 2025-12-12 | Completed · awaiting
Updated 9mo ago
| NCT07214740 |
Upcoming ophthalmology readouts — next 12 months
· 17Industry Phase 3 ophthalmology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Rophibio, Inc. | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration Asset: RBS-001 Solution for intravitreal injection | Neovascular Age-related Macular Degeneration (nAMD) | Not Yet Recruiting | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 17mo ago
| NCT06470373 |
| Salutaris Medical Devices, Inc. | Adjunct Episcleral Brachytherapy for PCV Asset: Aflibercept Injection | Age-Related Macular Degeneration +1 | Not Yet Recruiting | Q3 2026 2026-09 (est.) | Estimated · stale
Updated 37mo ago
| NCT05251636 |
| EyePoint Pharmaceuticals, Inc. | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 Asset: EYP-1901 | Wet Age Related Macular Degeneration +1 | Active Not Recruiting | Q4 2026 2026-10 (est.) | Estimated · fresh
Updated 6mo ago
| NCT06683742 |
| AbbVie | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Asset: Aflibercept (EYLEA®) | AMD +5 | Active Not Recruiting | Q4 2026 2026-10 (est.) | Estimated · fresh
Updated 5mo ago
| NCT05407636 |
| AbbVie | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease Asset: ABBV-444 | Dry Eye Disease | Completed | Q4 2026 2026-11 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07284381 |
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.